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http://www.biomedcentral.com/1471-2407/14/296RESEARCH ARTICLE Open AccessGastric Helicobacter pylori infection associates
with an increased risk of colorectal polyps in
African Americans
Hassan Brim1†, Marwah Zahaf2†, Adeyinka O Laiyemo2, Mehdi Nouraie3, Guillermo I Pérez-Pérez4, Duane T Smoot2,
Edward Lee1, Hadie Razjouyan6 and Hassan Ashktorab2,5*Abstract
Background: Gastric Helicobacter pylori (H. pylori) infection and colorectal polyps are more prevalent in African
Americans than in the general population. We aimed to investigate whether gastric H. pylori infection is associated
with colorectal polyps in African Americans.
Methods: Medical records of African Americans, 40 years and older (n = 1256) who underwent bidirectional
gastrointestinal endoscopy on the same day were reviewed. H. pylori status was assessed by immunohistochemistry
on gastric specimens. Colorectal polyps were confirmed by histological examination of colorectal biopsies. A subset
of serum samples from healthy and polyp-bearing patients (n = 163) were analyzed by ELISA for anti-H. pylori and
anti-CagA antibodies. The crude and adjusted effect of H. pylori on the risk of colorectal adenoma and polyp were
computed by logistic regression models.
Results: The prevalence of colorectal polyps and adenomas were 456 (36%) and 300 (24%) respectively. Colorectal
polyps were more prevalent in gastric H. pylori infected than non-infected subjects [43% vs. 34%; Odds Ratio (OR) (95%
CI): 1.5 (1.2-1.9), P = 0.001]. Patients with H. pylori-associated chronic active gastritis were at high risk to have adenomas
[Unadjusted OR (95% CI): 1.3 (1.0-1.8); P = 0.04]. There was no difference in histopathology, size, or location of polyps
with respect to H. pylori status. Gastric H. pylori infection, age, male gender and high risk clinical presentations were
independent risk factors for colorectal polyps. Serological testing also revealed a higher prevalence of H. pylori and its
toxin Cag-A in polyp patients vs. non polyp patients’ sera, although in a non-statistically significant manner.
Conclusions: This study showed that current gastric H. pylori infection is associated with an increased risk of colorectal
polyps in African Americans. Patients with H. pylori induced gastritis may benefit from early screening colonoscopy as a
preventative measure for colorectal cancer.
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Colorectal cancer (CRC) is the third most common cancer
and the third most common cause of cancer deaths in
both men and women in US [1]. In its sporadic form,
CRC mostly arises from adenomatous polyps (adenomas).
CRC can also arise from hyperplastic polyps [2,3]. Early* Correspondence: hashktorab@howard.edu
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reproduction in any medium, provided the ordetection and removal of colorectal polyps have led to a
decrease in the incidence and mortality from CRC [4-6].
Recent interest have been directed toward CRC preven-
tion and the possible role of infectious agents in the polyp
to cancer sequence [7-10]. For instance, many epidemio-
logical studies have linked H. pylori’s infection to colorec-
tal neoplasm either through high prevalence of H. pylori
seropositivity among CRC or colorectal polyp patients
[11-14], or through the presence of bacterial byproducts
and their trophic effects on colon mucosa [15-18], whiled. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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current H. pylori in the stomach [23] or colon [24-29]
with colon cancer and/or polyps.
It is well known that H. pylori predisposes to the de-
velopment of gastric cancer precursor lesions, thus it
has been classified as class 1 carcinogen [30]. A recent
publication by Sonneberg et al. revealed a wide range of
effects of gastric H. pylori on the gastrointestinal tract
with diseases that are inversely associated with H. pylori,
such as reflux disease, erosive oesophagitis, Barrett’s
oesophagus, and oesophageal adenocarcinoma, show-
ing a striking rise during the recent decline of H. pylori
infection in the general population [31]. Whether H.
pylori’s effect on gastric mucosa predicts its effect on
colon mucosa is still controversial. Indeed, a recent
meta-analysis of the correlation between H. pylori and
extra-gastric malignancies revealed a modest statistically
significant relationship of H. pylori infection with both
colon cancer and polyps [32]. H. pylori’s infection and
colorectal lesions appear to be more common in African
Americans compared to the Caucasian population in the
US [1,33]. We sought to determine whether current gas-
tric H. pylori infection was associated with the presence of




We retrospectively reviewed the medical records of 1920
patients of which 1256 were included in the present
study. The 1256 retained records correspond to African
American patients, 40 years and older who underwent
bidirectional endoscopy (complete colonoscopy and gas-
troscopy) at the same day from January 2005 to August
2009. The study was conducted at Howard University
Hospital, a tertiary hospital serving predominantly African
Americans in the District of Columbia, USA. The study
was approved by the Howard University Hospital Institu-
tional Review Board and we obtained consent from pa-
tients who provided blood samples for the serological
analysis. Demographic variables included gender, race and
age. Clinical and pathological data were collected with re-
spect to reasons for undergoing bidirectional endoscopies,
H. pylori immunohistochemistry (IHC) status of gastric
biopsies, histo-pathological diagnosis of gastric specimens,
and colorectal polyps’ type, size, grade of dysplasia and lo-
cation. We divided our patients into high and average risk
for colorectal polyps based on their presentations [34,35].
High risk patients were those with lower gastrointestinal
(GI) blood loss, abdominal mass [34,35], and/or family/
personal history of colorectal polyps or cancer [36]. Aver-
age risk patients were either asymptomatic and undergo-
ing screening colonoscopy or suffered abdominal pain,
epigastric pain unresponsive to treatment, acid pepticsymptoms, change in bowel habits, weight loss or anemia.
Patients were excluded if they had inflammatory bowel
disease, malignancies including colorectal cancer, subopti-
mal bowel preparations, incomplete colonoscopies, and
lack of data regarding H. pylori immunohistochemistry
examination of gastric biopsies.
Specimens
Gastric biopsies were taken during gastroscopy and were
labeled as antrum, body, and fundus. Both gastric biop-
sies and colorectal polyps (when encountered) were har-
vested by biopsy, snare, piecemeal excision, or saline
assisted endoscopic mucosal resection. Colorectal polyps
were divided by location. Polyps located in cecum, as-
cending, and transverse colon were classified as “right
sided”. Those located in descending colon, sigmoid, and
rectum were classified as “left sided”. Patients with mul-
tiple polyps all over the colon were classified as having
“both” right and left colon polyps. All specimens were
sent to the pathology department after immersion in for-
malin. The colorectal polyps size was measured after tissue
fixation. H. pylori status was identified using immunohisto-
chemistry staining on gastric biopsies. A Novocastra
Liquid mouse monoclonal Anti-H. pylori antibody was
used (NCL-L-H. pylori, Clone#ULC3R, Leica Biosys-
tems). An experienced gastrointestinal pathologist ex-
amined the specimens and made the histo-pathological
classification of gastric biopsies and colorectal polyps.
We classified H. pylori associated gastric lesions (inde-
pendently of their distribution or severity) into chronic
active (non-atrophic) gastritis, chronic atrophic gastritis
with intestinal metaplasia, reactive gastropathy with
foveolar hyperplasia, hyperplastic gastropathy and nor-
mal gastric mucosa [37]. We excluded gastric dysplasia
and gastric cancers from our study. Colorectal polyps
included hyperplastic (non-neoplastic) polyps and ad-
enomatous (neoplastic) polyps. Adenomatous polyps
were divided into advanced adenomas (tubular aden-
oma ≥1 cm, adenoma with > 25% villous component,
and/or high grade dysplasia), and non-advanced aden-
oma (tubular adenoma <1 cm) [6].
Serological tests for the detection of anti-H. pylori and
anti-Cag-A in patients’ sera
We determined the presence of anti-H. pylori antibodies
in serum using 96-well plates coated with H. pylori whole
cell antigens, according to previously described methods
[38,39]. All samples, standards and controls were run in
duplicate. Serum samples (n = 163) were diluted 1:800 and
incubated in the 96-well plate for 1 hr at 37°C. After wash-
ing the plates twice using EL × 50 Automated strip washer
(Bio-Tek Instruments, Winooski VT), bound antibodies
were detected by anti-human IgG linked to horseradish
peroxidase (Biosource International, Camarillo, CA) diluted









- No gastric lesion, n (%) 8 (2) 691 (78) <0.001
- Chronic Active Gastritis, n (%) 305 (83) 62 (7)
- Intestinal metaplasia, n (%) 46 (13) 98 (11)
- Other lesions, n (%) 7 (2) 35 (4)
Polyp, no (%)1 158 (43) 298 (34) 0.001
Polyp size in cm, mean (SD)1* 0.2 (0.15) 0.2 (0.15) 0.2
Polyp Histology*
- Advanced Adenoma, n (%) 21 (13) 32 (11) 0.6
- Non-advanced adenoma, n (%) 87 (55) 160 (54)
- Hyperplastic polyp, n (%) 50 (32) 106 (36)
Polyp Location1*
- Right side, n (%) 51 (32) 95 (32) 0.9
- Left side, n (%) 84 (53) 164 (55)
- Both sides, n (%) 23 (15) 38 (13)
1“Polyp” label in this table includes adenoma and hyperplastic polyp.
*Among subjects with polyps.
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color development is produced by 2,2′-Azino-bis(3-
Ethylbenzthiazoline-6-sulfonic acid) (Sigma Chemical
Co. St Louis MO). Color in wells was analyzed in a
MRX Revelation microplate reader (Dynex technologies
INC, Chantilly, VA) at 450 nm within 30 min. All assays
were performed with 4 positive and 2 negative controls.
A positive result is one with an OD (optical density) ra-
tio greater than one, as previously reported [40,41]. The
specificity of this assay is 93.5% and its sensitivity is
99.4% [40,42].
For the detection of antibodies against CagA, 96-well
plates coated with recombinant CagA protein prepared
according to specifications previously reported [43,44].
All samples, were run in duplicate. Serum samples were
diluted 1:100 and applied to wells and incubated for 1 hr
at 37°C. Plates were washed twice and bound antibodies
were detected by anti-human IgG linked to horseradish
peroxidase (Biosource). The reporter for bound enzyme
is horseradish peroxidase that was detected as mentioned
above. Color is read in a microplate reader (Dynex) at
450 nm. Samples with OD ratio values greater than a pre-
established cut-off (OD ratio 450 = 0.350) are considered
positive as previously reported [44]. This assay has a speci-
ficity of 97% and a sensitivity of 96% [43]. Positive and
negative controls were sera from biopsy- and culture-
validated individuals obtained locally, in addition to positive
and negative controls obtained from previous studies [38].
Statistical analysis
We used Student’s t-test to compare the distribution of
continuous variables between H. pylori positive and
negative subjects. For categorical variables, we used
Chi-square test. Then we computed unadjusted Odds
Ratio (OR) (95% Confidence Interval [CI]) for potential
predictors of colorectal polyps and adenomas. Multi-
variate logistic regression analysis was applied to compute
the adjusted OR (95% CI) for predictors of colorectal
polyps and adenomas. All variables with P < 0.2 from bi-
variate analysis were selected for multivariate logistic re-
gression. The final model was developed with a stepwise
backward approach. All variables with P value < 0.05 were
considered statistically significant and remained in final
model. All analyses were done using SPSS 17.0 (SPSS
Inc., IL).
Results
Population and clinicopathological characteristics
Among 1920 potential participants, 1256 African Americans,
aged forty or above, were eligible for this study. Non-
African American patients (n = 100), as well as patients
without bidirectional endoscopy (n = 385), patients with
inflammatory bowel disease (n = 146) or lacking the H.
pylori IHC stain (n = 33) were excluded. The prevalenceof H. pylori infection was 366/1256 (29.1%) while the
prevalence of colorectal polyps and adenomas were 456
(36%) and 300 (24%) respectively. The frequency of
males was 433 (34%). The frequency of colorectal aden-
omas increased with age (from 15% in patients younger
than 50 to 33% in those 70 years and older, p < 0.001).
The same trend was observed for polyps (from 30% in
patients younger than 50 to 39% in those 70 years and
older, P = 0.033). The mean age (SD) 57 years (9.6) was
the same for H. pylori infected and non-infected subjects
(p = 0.9). The frequency of male gender in H. pylori nega-
tive and positive patients were 32% and 41%, respectively
(p = 0.004). The frequency of chronic active gastritis
(p <0.001) and colon polyps (p = 0.001) were higher in
H. pylori positive patients. Polyp histology, size and loca-
tion were not correlated to H. pylori status (Table 1).
Colorectal polyps were located mainly in the left colon
(54%). The same distribution was observed for adenoma-
tous and hyperplastic polyps. Out of 1256 patients, 158
(13%) had personal or family history of colorectal polyps
or cancer. Of these 158 subjects, 63 (40%) were males, 32
(20%) were H. pylori positive, and 77 (49%) had colorectal
polyps.
By univariate analysis, older age (p <0.001), male gender
(p < 0.001), H. pylori positivity (p = 0.003) and chronic ac-
tive gastritis (p = 0.04) were significantly associated with
higher frequency of adenoma (Table 2.a). In a separate
analysis, male gender and H. pylori were associated with
higher frequency of polyps (Table 2.b).
Table 2 Univariate analysis of demographic and clinical variables by adenoma or polyp diagnosis
2.a: Adenoma Adenoma positive N = 300 Adenoma negative N = 956 OR (95% CI)* P value*
Age≥ 60 years, n (%) 129 (43) 295 (31) 1.7 (1.3-2.2) <0.001
Male gender, n (%) 132 (44) 301 (32) 1.7 (1.3-2.2) <0.001
H. pylori positivity, n (%) 108 (36) 258 (27) 1.5 (1.2-2.2) 0.003
Chronic active gastritis, n (%) 102 (34) 265 (28) 1.3 (1.0-1.8) 0.04
Baseline high risk, n (%) 8 (3) 13 (1) 2.0 (0.7-5.2) 0.1
2.b: Polyp Polyp positive N = 456 Polyp negative N = 800 OR (95% CI)* P value*
Age≥ 60 years, n (%) 169 (37) 255 (32) 1.3 (1.0-1.6) 0.06
Male gender, n (%) 177 (39) 256 (32) 1.3 (1.1-1.7) 0.015
H. pylori positivity, n (%) 158 (35) 208 (26) 1.5 (1.2-1.9) 0.001
Chronic active gastritis, n (%) 146 (32) 221 (28) 1.2 (1.0-1.6) 0.1
Baseline high risk, n (%) 13 (3) 8 (1) 2.9 (1.2-7.1) 0.014
*Unadjusted values.
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for each 10 years), male gender (adjusted OR = 1.7), and H.
pylori positivity (adjusted OR = 1.5) were independent risk
factors for colorectal adenoma (Table 3.a), with similar
findings for colorectal polyps (Table 3.b).Pre-procedure’s indications as risk predictors for
colorectal polyps
Using combination criteria of baseline high risk clinical
presentations- such as lower GI blood loss, abdominal
mass and/or family/personal history of colorectal polyps
or cancer, was more sensitive and specific than using
each presentation alone in the prediction of colorectal
polyps, but not adenoma (Table 2). In multivariate logis-
tic regression, baseline risk features were statistically sig-
nificant predictors of colorectal polyps (adjusted OR
[95% CI]: 2.9 [1.2-7.1]; p = 0.021).Table 3 Multivariate logistic regression for predictors of
colorectal adenoma or polyp
3.a: Adenoma Adjusted OR (95% CI)* P value
Age (10 years) 1.4 (1.2-1.6) <0.001
Male gender 1.7 (1.3-2.0) <0.001
H. pylori positivity 1.5 (1.1-2.0) 0.003
3.b: Polyp Adjusted OR (95% CI)* P value
Age (10 years) 1.2 (1.1-1.3) 0.005
Male gender 1.3 (1.0-1.7) 0.026
H. pylori positivity 1.5 (1.2-1.9) 0.002
Baseline high risk 2.9 (1.2-7.1) 0.021
Variables entered into each model were Age, gender, H. pylori status, chronic
active gastritis, baseline high risk.
*OR are simultaneously adjusted for the rest of variables remained in
the model.Serological assays for the detection of anti-H. pylori and
anti-Cag-A
One hundred sixty three serum samples (including 81
polyp and 82 without polyps gender and age matched
subjects) were analyzed for anti-H. pylori and anti-Cag-
A antibodies. In these two groups, 85 subjects (45%)
were positive for anti-H. pylori. Of these 85 sera, 60
(71%) were anti-Cag-A positive. The anti-H. pylori posi-
tive number in non polyp patients were 40 (49%) while
they were 45 (56%) in the polyp patients’ sera (p = 0.3)
while anti-Cag-A positivity was 73% in polyp patients vs.
68% in non polyp controls (p = 0.5). Thirty three (55%)
patients who were positive for both H. pylori and Cag-A
had polyps while 33 (47%) patients of those negative for
both H. pylori and Cag-A had polyps (p = 0.3; Table 4).
The corresponding figure for those positive for H. pylori
and negative for Cag-A was 12 (48%). While the p values
were not statistically significant, the observed pattern of
higher polyp prevalence in H. pylori/Cag-A patients is
consistent with the overall epidemiological results.
Discussion
Our study indicates that gastric H. pylori infection, con-
firmed by immunohistochemistry staining of gastricTable 4 Serological testing for anti-H. pylori (HP) and
anti-Cag-A in patients with polyps
H. pylori status Number of
patients
Polyps OR (95% CI)*
HP Negative 70 33 (47%) 1
HP Positive
HP Ab + & Cag Ab + 60 33 (55%) 1.37 (0.65-2.90)
HP Ab + & Cag Ab – 25 12 (48%) 1.03 (0.37-2.85)
HP Ab - & Cag Ab + 8 3 (38%) 0.67 (0.10-3.79)
Total 163 81 (50%)
*Unadjusted.
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lesions in African Americans. The same association was
true in 3 meta-analyses which included studies from dif-
ferent ethnic groups. In particular, Zumkeller et al. [45]
included 11 studies regardless of the diagnostic tests
used for H. pylori, and Zhao et al. [13] included 10 out
of 13 case–control studies that used only IgG antibody
for H. pylori to demonstrate previous H. pylori infection in
patients with colonic lesions. Jones et al. [46] used immu-
nohistochemistry methods to demonstrate that H. pylori
do reside in the subjects’ colon biopsies and associates
with colorectal neoplasm.
Our previous report showed colorectal polyps’ incidence
begins to increase significantly at age forty in African
Americans [47] with or without family history of CRC,
thus it has been chosen as a cutoff age in this study. Aging
male patients are at a higher risk of adenomatous and hy-
perplastic polyps [48], and are more likely to associate
with H. pylori positivity which is consistent with findings
in other ethnic groups [49]. In this study, we were not able
to establish a correlation between histopathological sub-
types, size, and location of colorectal polyps with H. pylori
infection.
Other confounders such as BMI, smoking, alcohol
consumption, diabetes, socioeconomic status, diet and
lack of physical activity are known risk factors for colo-
rectal polyp/cancer. Our retrospective epidemiological
study did not adjust for these factors because of lack of
corresponding information. Previous studies reported an
association between H. pylori and colorectal adenoma
which was not altered even after adjustment for con-
founding factors [14,50].
To our knowledge, no previous study has linked H. pylori
infection with colorectal polyps or cancer in African
Americans. The higher prevalence of colorectal polyps
in H. pylori infected patients and the higher seroposi-
tivity could be explained by their environmental and
genetic differences as well. Potentially, such differences
may alter host gastric and/or colorectal mucosa in re-
sponse to H. pylori carcinogenic effect among some
ethnic groups. For instance, Indians have a low rate of
gastric cancer and high rate of H. pylori infection which
was not significantly associated with intestinal metapla-
sia, gastric tumor site, and patient’s age [51]. Moreover,
despite the high prevalence of gastric cancer in Finland,
there was no association between atrophic gastritis or
H. pylori infection with colorectal cancer among
Finnish male smokers [19,52].
High risk features when combined at presentation
were more predictive for colorectal polyps, As such, they
can be useful clinical criteria to prioritize access to col-
onoscopy. The risk prediction of colorectal polyps based
on gastric lesions recovered from gastroscopy depend on
the nature of such lesions. The highest prevalence ofcolorectal polyps among H. pylori positive subjects was
found among those who had chronic active gastritis.
Such polyps were more likely to be neoplastic (aden-
omatous). Due to the retrospective nature of the study,
the time lapse between the H. pylori infection and the
colonic lesions occurrence is unknown. Meira et al. [8] re-
ported after infecting mice with H. pylori, the chronic in-
flammation induced DNA damage in alkyladenine DNA
glycosylase deficit mice and enhances inflammation-
associated colon tumorigenesis. It also predisposed to the
development of gastric cancer precursor lesions.
As gastric lesions progressed, H. pylori positivity de-
creased and the risk of colorectal polyps increased, being
highest in patients with chronic atrophic gastritis with
intestinal metaplasia, but the number of associated colo-
rectal polyps was too small to make meaningful conclu-
sions. The annual progression from chronic non-atrophic
gastritis to atrophic gastritis is 1 to 3% [53,54]. H. pylori in
advanced gastric lesions has probably decreased because
of migration through the gastrointestinal tract [55]. This
suggests that with advanced gastric lesions, gastric lesions
but not H. pylori status would be appropriate in the pre-
diction of colorectal polyps [23,56,57]. Bulajic et al. [24]
found only 1.2% of malignant colorectal tissues were posi-
tive for H. pylori in contrast to 6% positive normal tissues
from cancer patients. This could be explained by migra-
tion phenomena too [46] and would suggest that H. pylori
gastric effect could be similar to its colonic effect. Once
H. pylori’s infection is established, it likely elicits robust
and lasting inflammatory and immune responses that
may potentially influence the development of diseases
that occur later in life such as cancer.
The strengths of our study; are in its comprehensive
nature since it linked the real time presence of gastric
H. pylori, the symptoms it may produce, and the associ-
ated gastric lesions with its extra-gastric colonic effects
[58]. Gold standard tools were utilized to diagnose
colorectal polyps (complete colonoscopy) and H. pylori
infection (gastric biopsy). We used immunohistochem-
istry to diagnose H. pylori in gastric biopsies as it is
highly sensitive and specific particularly in patients who
have been partially treated. Besides, we had a fairly large
sample size (n = 1256). Moreover, the findings with this
large sample were further confirmed serologically.
Because our study was retrospective and hospital-
based rather than population-based, it has its own limi-
tations. The underestimation of H. pylori’s prevalence
and its associated gastric lesions in the prediction of
colorectal polyps could be explained by gastric sampling
errors and unknown received treatments. Also, our ser-
ology testing sampling was smaller (n = 163) than the
sampling for the epidemiological study (n = 1256). Des-
pite that, we were able to prove positive association be-
tween H. pylori and colorectal polyps consistent with the
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able to show that there is a trend of increased chance of
having polyps in the presence of Cag-A positive H. pylori
infections.
Conclusions
In conclusion, forty years and older African Americans
with gastric H. pylori infection were at high risk of neo-
plastic and non-neoplastic colonic lesions. H. pylori as-
sociated chronic active gastritis and alarming clinical
features at presentation may necessitate early screening
colonoscopy and/or H. pylori eradication. Prospectively
designed studies are needed to establish the conditions
in which the current H. pylori infection in gastric muco-
sal lesions might participate in the colon carcinogenic
transformation, either through its colonization of the
colon and/or through its metabolites and whether the
eradication of H. pylori would reduce colon polyp inci-
dence in African Americans in the future.
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